Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of eukaryotic translation initiation factor EIF4B as Ebola virus disease treatment target

A technology of translation initiation factor and Ebola virus, which is applied in the field of biomedicine to achieve the effect of reducing replication

Active Publication Date: 2022-05-13
ACADEMY OF MILITARY MEDICAL SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current effective prevention and control strategy against Ebola virus is still a world problem that needs to be solved urgently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of eukaryotic translation initiation factor EIF4B as Ebola virus disease treatment target
  • Application of eukaryotic translation initiation factor EIF4B as Ebola virus disease treatment target
  • Application of eukaryotic translation initiation factor EIF4B as Ebola virus disease treatment target

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] In this example, co-immunoprecipitation was used to confirm the interaction between EIF4B and VP35. VP35 is an important structural protein in the replication process of Ebola virus.

[0027] The specific experimental method is as follows:

[0028] (1) Construction of expression vectors of Myc-EIF4B and Flag-VP35. The build method is:

[0029] Taking the construction of Myc-EIF4B expression plasmid as an example, the relevant experimental steps are described. As follows: search for the EIF4B gene sequence on the database NCBI, use primer5 to design EIF4B amplification primers, which are synthesized by Beijing Nuosai Genome Research Center Co., Ltd.; PCR amplifies the target fragment, use EcoRI and XhoI for double digestion at 37°C, and agar The digested products were recovered after gel electrophoresis. Use T4 ligase to react it with PCMV-Myc vector at 16°C for more than 2 hours, transform DH5α competent cells, and spread the bacterial solution evenly on the solid L...

Embodiment 2

[0034] In this example, immunoblotting was used to screen the siRNA with the highest efficiency of knocking down EIF4B, the method is as follows:

[0035] (1) Two pairs of 0.15nmol siRNA were transfected into 293 cells (six-well plate) using TransIT X2 transfection reagent, and the cells were harvested after 72 hours. Aspirate the medium first, collect and resuspend the cells in pre-cooled 1×PBS, wash 3 times, and discard the supernatant completely. After adding cell lysate (Tris-HCl 50mM pH8.0, NaCl 150mM, 1% NP40, protease inhibitor 1 piece / 50ml), place on ice for 30min, centrifuge at 12000rpm at 4°C for 10min, pipette 60μl supernatant to clean 1.5ml EP Add 15 μl of 5×SDS-PAGE loading buffer into the tube, bathe in boiling water for 10 minutes, centrifuge at 4°C and 8000 rpm for 3 minutes, take 10 μl of the supernatant for polyacrylamide gel electrophoresis (SDS-PAGE), after electrophoresis at 80V for 30 minutes, put Adjust the voltage to 120V until bromophenol blue migrate...

Embodiment 3

[0049] In this example, the Ebola minimal genome was used to detect the effect of EIF4B siRNA on virus replication. In this example, the Ebola minimal genome is used to simulate the life cycle of Ebola virus under biosafety level 2 conditions. In this system, a 4-cistronic minigenome (minigenome, MG) was formed by linking the renilla luciferin reporter gene (RLUC) with the virus genome lacking NP, VP35, and L. When MG and NP, VP35, L and T7 polymerase are co-transferred into 293 cells, the virus can replicate and produce virus particles containing MG (without self-replicating ability). When the virus replicates, RLUC is also expressed. Therefore, the virus replication can be evaluated by detecting the value of RLUC with a dual-luciferase detection kit. That is, the higher the RLUC value, the higher the virus replication level.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of an eukaryotic translation initiation factor EIF4B (Gene ID: 1975) as an Ebola virus disease treatment target. The application comprises the step of preparing a product for preventing Ebola virus infection or treating Ebola virus diseases by adopting a substance capable of inhibiting EIF4B expression. Experiments prove that after cells are treated with the eukaryotic translation initiation factor EIF4B siRNA, Ebola virus replication is remarkably reduced, and it is proved that the EIF4B siRNA can effectively inhibit Ebola virus proliferation. The invention further screens out siRNA (small interfering Ribonucleic Acid) with a remarkable knock-down effect on EIF4B (Ebola Induced Factor 4B), and the siRNA has a better effect of inhibiting the proliferation of the Ebola virus. The invention provides a new treatment strategy for prevention and treatment of acute infectious diseases caused by Ebola virus infection.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of eukaryotic translation initiation factor EIF4B as a therapeutic target for Ebola virus disease. Background technique [0002] Ebola virus disease (EVD) is a severe zoonotic infectious disease caused by Ebola virus (EBOV). Since its discovery in 1976, it has repeatedly broken out in Africa. Ebola virus belongs to filovirus, which is an enveloped single-stranded negative-sense RNA virus, which can cause acute hemorrhagic infectious diseases in humans and non-human primates, with a mortality rate of about 50%-90%. The genome sequence of Ebola virus is 3' non-coding region-NP-VP35-VP40-GP-VP30-VP24-L-5' non-coding region, which can encode nucleoprotein NP, virion protein VP35, matrix protein VP40, Glycoprotein GP, ​​VP30, VP24, RNA-dependent RNA polymerase L, a total of 7 structural proteins. Although Ebola initially targets macrophages and dendritic cells, it eventual...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/7088A61P31/14
CPCA61K45/00A61K31/7088A61P31/14
Inventor 刘海楠曹诚刘萱张迅柏宇
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com